← All trials
NCT03253887
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2016
- Primary completion
- Apr 30, 2017
- Completion date
- Oct 31, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Instituto de Medicina Integral Professor Fernando FigueiraLead sponsor
- Instituto de Medicina Integral Professor Fernando FigueiraOverall official - principal investigator
- Instituto de Medicina Integral Professor Fernando FigueiraReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.